Research and Markets: Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2013 Research Report

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/mnfwnf/gastroesophageal) has announced the addition of the "Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2013" report to their offering.

'Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas.

Scope

- A snapshot of the global therapeutic scenario for Gastroesophageal (GE) Junction Carcinomas.

- A review of the Gastroesophageal (GE) Junction Carcinomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Gastroesophageal (GE) Junction Carcinomas pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Key Topics Covered:

Introduction

Gastroesophageal (GE) Junction Carcinomas Overview

Therapeutics Development

Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Overview

Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis

Gastroesophageal (GE) Junction Carcinomas - Therapeutics under Development by Companies

Gastroesophageal (GE) Junction Carcinomas - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Gastroesophageal (GE) Junction Carcinomas - Products under Development by Companies

Gastroesophageal (GE) Junction Carcinomas - Companies Involved in Therapeutics Development

Gastroesophageal (GE) Junction Carcinomas - Therapeutics Assessment

Drug Profiles

pertuzumab - Drug Profile

onartuzumab - Drug Profile

olaparib - Drug Profile

ipilimumab - Drug Profile

trebananib - Drug Profile

alisertib - Drug Profile

varlitinib - Drug Profile

MM-111 - Drug Profile

MEDI-4736 - Drug Profile

R&D Progress

Featured News & Press Releases

Appendix

Companies Mentioned

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd.

Amgen Inc.

AstraZeneca PLC

MedImmune, LLC

Millennium Pharmaceuticals, Inc.

Merrimack Pharmaceuticals, Inc.

Aslan Pharmaceuticals Pte. Ltd.

For more information visit http://www.researchandmarkets.com/research/mnfwnf/gastroesophageal

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology